Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on The Middle East Health Journal.
Press releases published on April 22, 2025
Standard BioTools Schedules First Quarter Earnings Conference Call on May 6, 2025
GlobeNewswire
·
April 22, 2025
SOUTH SAN FRANCISCO, Calif., April 22, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) today announced that it will report first quarter 2025 financial results on Tuesday, May 6, 2025, after market close. The company will host a conference …
Orchestra BioMed Receives FDA Breakthrough Device Designation for AVIM Therapy
GlobeNewswire
·
April 22, 2025
Breakthrough Device Designation (“BDD”) applies to an estimated U.S. population of over 7.7 million patients with uncontrolled hypertension and increased cardiovascular risk BDD also encompasses pacemaker-indicated patients with uncontrolled hypertension …
Rapport Therapeutics to Participate in Upcoming Investor Conferences
GlobeNewswire
·
April 22, 2025
BOSTON and SAN DIEGO, April 22, 2025 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP) (“Rapport” or the “Company”), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for …
Medicenna to Present at the 2025 Bloom Burton & Co. Healthcare Investor Conference
GlobeNewswire
·
April 22, 2025
TORONTO and HOUSTON, April 22, 2025 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQX: MDNAF), a clinical-stage immunotherapy company focused on the development of Superkines targeting cancer and autoimmune …
Aclaris Therapeutics Secures U.S. Food and Drug Administration IND Clearance for ATI-052, Enabling Advancement of its Novel Bispecific Anti-TSLP/IL-4R Investigational Antibody
GlobeNewswire
·
April 22, 2025
- Initiation of Upcoming Phase 1a/1b Clinical Trial Expected in the Second Quarter of 2025 - WAYNE, Pa, April 22, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel …
Arch Biopartners Announces Toronto General Hospital Ethics Board Approval to Join the Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury (CS-AKI)
GlobeNewswire
·
April 22, 2025
TORONTO, April 22, 2025 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that the University Health Network (UHN) Research Ethics Board has granted approval for Toronto General …
BioNTech veröffentlicht am 5. Mai 2025 Ergebnisse für das erste Quartal 2025 und informiert über operativen Fortschritt
GlobeNewswire
·
April 22, 2025
MAINZ, Deutschland, 22. April 2025 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, „BioNTech“ oder „das Unternehmen“) wird am Montag, den 5. Mai 2025, die Ergebnisse für das erste Quartal 2025 veröffentlichen. Darüber hinaus wird das Unternehmen am selben …
BioNTech to Report First Quarter 2025 Financial Results and Corporate Update on May 5, 2025
GlobeNewswire
·
April 22, 2025
MAINZ, Germany, April 22, 2025 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will announce its financial results for the first quarter 2025 on Monday, May 5, 2025. Additionally, the Company will host a conference call and …
Amesite Announces NurseMagic™ Meets HIPAA Requirements for Individuals Users, in Addition to Enterprises
GlobeNewswire
·
April 22, 2025
DETROIT, April 22, 2025 (GLOBE NEWSWIRE) -- Amesite Inc. (NASDAQ: AMST), a leading technology company specializing in the development and marketing of B2C and B2B AI-driven solutions, today announced NurseMagic™ now meets HIPAA requirements for all users. …
AscellaHealth Demonstrates Leadership in Realizing the Full Potential of Novel Therapies and Medicinal Products at Advanced Therapies Integrates North 2025
GlobeNewswire
·
April 22, 2025
DUBLIN and BERWYN, Pa., April 22, 2025 (GLOBE NEWSWIRE) -- AscellaHealth, a global partner delivering customisable solutions to support the specialty pharmaceutical industry, proudly announces its participation in Advanced Therapies Integrates North 2025, …
R3 Vascular Announces First Patient Treated in ELITE-BTK Pivotal Trial for Below-the-Knee PAD Using MAGNITUDE® Drug Eluting Bioresorbable Scaffold
GlobeNewswire
·
April 22, 2025
MOUNTAIN VIEW, Calif., April 22, 2025 (GLOBE NEWSWIRE) -- R3 Vascular Inc., a medical device company dedicated to developing and providing novel, best-in-class bioresorbable scaffolds for treating peripheral arterial disease (PAD), is pleased to announce …
Regeneron Announces New Investment in Manufacturing of its Industry-Leading Biologic Medicines
GlobeNewswire
·
April 22, 2025
New manufacturing and supply agreement with FUJIFILM Diosynth Biotechnologies in North Carolina will enable additional production of Regeneron’s biologic medicines and support high-paying jobs in the region Regeneron’s ongoing and planned investments in …
PrimeBiome Reviews: “Gut–Skin Miracle” or Just Hype? Expert Insights
GlobeNewswire
·
April 22, 2025
St. Petersburg, Florida, April 22, 2025 (GLOBE NEWSWIRE) -- With over 19,000 customer reviews and rising buzz across wellness communities, Prime Biome is being hailed as a “gut–skin miracle”—but does it actually live up to the hype? Touted as a dual-action …
Prime Biome Reviews 2025: Updated Comprehensive Guide to the Revolutionary Gut & Skin Health Supplement!
GlobeNewswire
·
April 22, 2025
St. Petersburg, Florida, April 22, 2025 (GLOBE NEWSWIRE) -- Explore how PrimeBiome is transforming gut and skin health in 2025. This detailed review covers everything—from ingredients and expert opinions to real customer experiences—to help you decide if …
Lipella Reports Positive Phase 2a Results from Second LP-310 Cohort in Oral Lichen Planus; Final Data Expected Q2 2025
GlobeNewswire
·
April 22, 2025
Second Cohort Results Highlight Efficacy Across All Key Measures and Reinforce Safety of Twice-Daily Oral Rinse Phase 2a Study Now Fully Enrolled Across All Three Dose Cohorts Advancing Toward Phase 2b IND Submission and Broader Regulatory Engagement …
CARBOGEN AMCIS 上海工厂获得中国NMPA颁发的药品生产许可证
GlobeNewswire
·
April 22, 2025
瑞士布本多夫, April 22, 2025 (GLOBE NEWSWIRE) -- 总部位于瑞士的制药工艺开发与原料药（API）生产公司 CARBOGEN AMCIS 欣然宣布，其上海工厂已成功获得中国国家药品监督管理局（NMPA）颁发的首张药品生产许可证（DML）。 NMPA 的批准经过了严格审查，重点关注 GMP 合规性和运营准备情况。 上海工厂顺利满足了所有监管要求，反映出其运营日趋成熟，质量体系实力强大。 这一里程碑标志着 CARBOGEN AMCIS …
CARBOGEN AMCIS Shanghai Site Awarded Drug Manufacturing License from Chinese NMPA
GlobeNewswire
·
April 22, 2025
BUBENDORF, Switzerland, April 22, 2025 (GLOBE NEWSWIRE) -- CARBOGEN AMCIS, a Switzerland-based pharmaceutical process development and Active Pharmaceutical Ingredient (API) manufacturing company is pleased to announce that its Shanghai facility has …
Alpha Bites Gummies Reviews (WARNING) Is It Safe for Men’s Health? Understanding Its Natural Ingredients And Benefits!
GlobeNewswire
·
April 22, 2025
ORLANDO, Fla., April 22, 2025 (GLOBE NEWSWIRE) -- Any man looking for an easier and more effective way to increase their overall health and vitality must have come across several dietary supplements with different claims. Choosing the best from this big …
Telix Reports US$186M Q1 Revenue, Up 62% YOY
GlobeNewswire
·
April 22, 2025
MELBOURNE, Australia and INDIANAPOLIS, April 22, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, Telix, the Company) today provides an update on its commercial and operational performance for the quarter ended 31 March 2025 ( …
1STBIO and LigaChemBio Announce Strategic R&D and Licensing Option Agreement
GlobeNewswire
·
April 22, 2025
Expanded collaboration leverages complementary expertise to unlock next-generation oncology therapeutics Focus on breakthrough ADC payloads and immuno-oncology candidates with out-licensing potential YONGIN, South Korea, April 22, 2025 — 1ST …